Evotec (ETR:EVT) Stock Falls 0.2% – What’s Next?

Posted by on Sep 26th, 2026

Evotec SE (ETR:EVT – Get Free Report) fell 0.2% during mid-day trading on Thursday. The stock traded as low as €2.78 and last traded at €2.80. Approximately 792,348 shares traded hands during mid-day trading, a decline of 42% from the average daily volume of 1,360,000 shares. The stock had previously closed at €2.81.

Evotec Stock Up 2.0%

The stock’s 50 day moving average is €3.29 and its 200 day moving average is €4.29. The company has a market capitalization of $521.38 million, a PE ratio of -3.04, a PEG ratio of 0.98 and a beta of 1.26. The company has a debt-to-equity ratio of 71.50, a quick ratio of 2.97 and a current ratio of 2.33.

Evotec Company Profile

(Get Free Report)

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health. It has collaboration agreements with SK bioscience, JingXin, Carrick Therapeutics, Sernova, Topas Therapeutics, Exscientia, CONBA Group, Centrexion, Sanofi/NIH, Kazia Therapeutics, Bristol Myers Squibb, Topas Therapeutics, Immunitas, Exscientia, and Bayer, as well as a strategic partnership with Dewpoint Therapeutics to advance its portfolio targeting biomolecular condensates as a novel domain for therapeutic intervention towards the clinic.

Featured Articles

Receive News & Ratings for Evotec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evotec and related companies with MarketBeat.com's FREE daily email newsletter.